Thomson Reuters News

Thomson Reuters Launches New Biomarkers Solution

PHILADELPHIA and LONDON, June 17 PRNewswire-FirstCall — Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, announced today the launch of BIOMARKERcenter, a unique comprehensive resource for biomarker intelligence. This new solution will be the first to provide the pharmaceutical industry with a framework for assessing the potential of a biomarker and to be alerted of any changes in their status.

BIOMARKERcenter covers the biomarkers identified in literature, patents, conferences, clinical trial information, and other sources for all major therapeutic areas: oncology, cardiovascular diseases, diabetes, respiratory disorders, autoimmune diseases and neurological disorders. For each therapy area, it includes not only biomarkers with established clinical usage, but also emerging uses for the biomarker. Each record has been manually created by a team of Thomson Reuters experts and provides a unique report on the biomarker using a novel lifecycle model. Other data provided will include the name, classification, biological entities/processes involved, associated drugs, role or utilities, measurement techniques, regulatory status and related diagnostic kits.

Biomarkers are measurable indicators which can be used to define a biological state. Using Biomarkers as part of a pharmaceutical R&D program can increase the success of the project by encouraging innovation, improving efficiency, saving costs and delivering a valuable advantage over competitors.

"BIOMARKERcenter is the first reliable and comprehensive database of biomarkers available to the pharmaceutical and diagnostic industries. It sets a new standard for the presentation and analysis of Biomarker information," said Jon Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson Reuters. "Biomarkers have the capacity to change the way pharmaceutical companies develop drugs and bring them to the market. They allow companies to improve their clinical trials design, and better understand the biology of the diseases they are targeting, and we believe BIOMARKERcenter will become an essential tool for our customers."

This new solution will be available through several delivery methods: a standalone web solution, fully integrated into Prous Science's Integrity(R) platform, or as an XML feed to internal customer databases. The Integrity integration and XML feed are available currently, with the standalone solution to be delivered later in 2008.

For further information about BIOMARKERcenter, please go to: http://scientific.thomsonreuters.com/products/biomarkercenter/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.

SOURCE Thomson Reuters

Send this news item to a friend.

Print This Page